(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of 31.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.56%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Mersana Therapeutics's revenue in 2025 is $40,497,000.On average, 5 Wall Street analysts forecast MRSN's revenue for 2025 to be $4,088,406,445, with the lowest MRSN revenue forecast at $2,492,626,780, and the highest MRSN revenue forecast at $6,570,564,192. On average, 5 Wall Street analysts forecast MRSN's revenue for 2026 to be $7,751,570,760, with the lowest MRSN revenue forecast at $2,492,626,780, and the highest MRSN revenue forecast at $24,926,267,800.
In 2027, MRSN is forecast to generate $2,554,942,450 in revenue, with the lowest revenue forecast at $1,994,101,424 and the highest revenue forecast at $3,115,783,475.